Stifel Nicolaus Boosts Exelixis (NASDAQ:EXEL) Price Target to $51.00

Exelixis (NASDAQ:EXEL) had its target price lifted by Stifel Nicolaus from $47.00 to $51.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “hold” rating on the biotechnology company’s stock. Stifel Nicolaus’ target price would indicate a potential downside of 7.52% from the company’s current price.

A number of other equities analysts have also recently commented on EXEL. Morgan Stanley increased their target price on Exelixis from $50.00 to $53.00 and gave the company an “equal weight” rating in a report on Thursday, July 23rd. Barclays increased their price objective on Exelixis from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 14th. Zacks Research lowered shares of Exelixis from a “hold” rating to a “strong sell” rating in a report on Monday. Citizens Jmp increased their target price on shares of Exelixis from $50.00 to $55.00 and gave the company a “market outperform” rating in a research report on Wednesday, June 24th. Finally, Truist Financial boosted their price target on shares of Exelixis from $54.00 to $56.00 and gave the stock a “hold” rating in a research report on Tuesday, July 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $49.79.

Exelixis Trading Down 2.7%

NASDAQ:EXEL traded down $1.55 during trading hours on Thursday, reaching $55.15. 949,224 shares of the company were exchanged, compared to its average volume of 2,687,123. The firm has a market cap of $13.86 billion, a PE ratio of 18.34, a price-to-earnings-growth ratio of 1.62 and a beta of 0.44. Exelixis has a twelve month low of $33.76 and a twelve month high of $57.57. The stock’s 50-day moving average is $54.08 and its 200-day moving average is $47.84.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.06. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The business had revenue of $628.69 million for the quarter, compared to analyst estimates of $636.40 million. During the same quarter last year, the business earned $0.75 earnings per share. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. As a group, research analysts anticipate that Exelixis will post 3.15 EPS for the current year.

Insider Buying and Selling

In related news, CFO Christopher J. Senner sold 34,901 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the completion of the sale, the chief financial officer owned 952,317 shares of the company’s stock, valued at approximately $47,615,850. This represents a 3.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jack L. Wyszomierski sold 3,925 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $50.55, for a total transaction of $198,408.75. Following the sale, the director owned 284,384 shares of the company’s stock, valued at approximately $14,375,611.20. The trade was a 1.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 130,824 shares of company stock worth $6,555,231 over the last quarter. Corporate insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Exelixis

Several institutional investors and hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Exelixis by 81.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after acquiring an additional 19,407 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Exelixis by 4.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock worth $54,153,000 after acquiring an additional 68,133 shares during the last quarter. Focus Partners Wealth raised its position in Exelixis by 83.4% in the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock valued at $1,420,000 after purchasing an additional 17,483 shares during the period. Geneos Wealth Management Inc. lifted its stake in shares of Exelixis by 134.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 944 shares during the last quarter. Finally, Sivia Capital Partners LLC grew its holdings in shares of Exelixis by 23.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after purchasing an additional 2,764 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Exelixis reported second-quarter EPS of $0.91, above analyst expectations of approximately $0.85-$0.86 and up from $0.75 a year earlier. Revenue increased 10.6% year over year to $628.7 million, while net margin was 35.1%. Exelixis Tops Q2 Earnings Estimates
• Positive Sentiment: Management highlighted continued resilience from its Cabozantinib franchise, disciplined cost management and potential upside from zanzalintinib, including planned launches in colorectal cancer. TD Cowen reaffirmed its Buy rating, citing these factors, although its $55 price target is below the stock’s recent trading level. TD Cowen Reaffirms Buy Rating
• Neutral Sentiment: Zacks Research raised its third-quarter 2026 EPS estimate slightly to $0.77, while projecting full-year EPS of $3.12 in 2026, $3.60 in 2027 and $4.18 in 2028. These forecasts remain broadly consistent with continued earnings growth, but Zacks maintains a Strong Sell rating.
• Negative Sentiment: Exelixis lowered 2026 revenue guidance to $2.5 billion-$2.6 billion, putting the midpoint $50 million below the prior outlook and roughly in line with the consensus estimate’s lower end. The reduction, tied in part to near-term net revenue expectations, overshadowed the EPS beat. Exelixis Lowers 2026 Revenue Guidance
• Negative Sentiment: Zacks downgraded Exelixis from Hold to Strong Sell and trimmed its FY2026, FY2027 and FY2028 EPS estimates modestly, including a reduction in 2028 EPS from $4.28 to $4.18. The revisions reinforce investor concerns about longer-term growth expectations.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.